An interventional study of Dispersion ablation + PVI and VX1 in Atrial Fibrillation, sponsored by Volta Medical. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Volta Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.
Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 69th largest by enrollment of the 193 interventional ones that give a count, is one of 29 that started in 2021, is one of 117 with no phase, and was the 213th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
Volta Medical · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Boston Scientific Corporation · Sites in France, Belgium, Croatia and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 42 · Phase 4 24
First in 1999; this study’s year is marked. 29 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 377 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 193 interventional studies, 250 across the 123 observational. Of the 205 that completed or were terminated, 61 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 317 have an industry lead sponsor. The 10 most frequent:
Volta Medical is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Volta Medical has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
23 of the studies in Atrial Fibrillation with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05773638University Hospital, BrestCardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West | 2026-12-26 |
| NCT05777551Clinica MediterraneaAF Ablation With High Power Short Duration RF | 2026-12-31 |
| NCT05790707Poitiers University HospitalEfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment | 2027-01 |
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add all 23 to your calendar (.ics) → With an account.
Among the 317 studies in Atrial Fibrillation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI).
The hypothesis in this Study is that a tailored ablation strategy targeting areas of spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation strategy targeting PVI alone for the treatment of persistent AF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tailored ablation strategy
Procedure: Dispersion ablation + PVI · Device: VX1
Anatomical ablation strategy
Procedure: PVI
Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
VX1-based dispersion mapping
Pulmonary vein antrum isolation
Number of Participants Free From Documented AF After One Ablation Procedure
Freedom from documented AF episodes \> 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure
Time frame: 12 months
Number of Participants Free From Documented AF/AT After One or Two Ablation Procedures
Freedom from documented AF/AT episodes \> 30 seconds, after one or two procedures, with or without AADs, at 12 months
Time frame: 12 months
Number of Participants Free From Documented AF/AT After One Ablation Procedure
Freedom from documented AF/AT episodes \> 30 seconds, with or without AADs, 12 months after a single ablation procedure
Time frame: 12 months
Number of Participants With Complications (Safety Composite Endpoint)
Complications at 12 months: death, cerebrovascular events, or serious treatment-related adverse event
Time frame: 12 months
| Milestone | Tailored | Anatomical |
|---|---|---|
| Started | 188 | 186 |
| Completed | 174 | 174 |
| Not completed | 14 | 12 |
Freedom from documented AF episodes \> 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure
| Participants | Tailored | Anatomical |
|---|---|---|
| Number of Participants Free From Documented AF After One Ablation Procedure | 158 | 124 |
Freedom from documented AF/AT episodes \> 30 seconds, after one or two procedures, with or without AADs, at 12 months
| Participants | Tailored | Anatomical |
|---|---|---|
| Number of Participants Free From Documented AF/AT After One or Two Ablation Procedures | 136 | 126 |
Freedom from documented AF/AT episodes \> 30 seconds, with or without AADs, 12 months after a single ablation procedure
| Participants | Tailored | Anatomical |
|---|---|---|
| Number of Participants Free From Documented AF/AT After One Ablation Procedure | 108 | 106 |
Complications at 12 months: death, cerebrovascular events, or serious treatment-related adverse event
| Participants | Tailored | Anatomical |
|---|---|---|
| Number of Participants With Complications (Safety Composite Endpoint) | 8 | 5 |
Collected over 1 year after the study index ablation procedure. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tailored | 2/187 (1.1%) | 21/187 (11.2%) | 12/187 (6.4%) |
| Anatomical | 0/183 (0%) | 11/183 (6%) | 10/183 (5.5%) |
| Event | Tailored | Anatomical |
|---|---|---|
| Fluid overloadCardiac disorders | 9/187 | 3/183 |
| Pericarditis or pericardial effusionCardiac disorders | 4/187 | 0/183 |
| Vascular access complicationsVascular disorders | 3/187 | 3/183 |
| Cardiac tamponade or perforationCardiac disorders | 2/187 | 2/183 |
| BradycardiaCardiac disorders | 1/187 | 1/183 |
| Severe cardiac decompensationCardiac disorders | 1/187 | 1/183 |
| Puncture-site hemorrhageVascular disorders | 0/187 | 1/183 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/187 | 1/183 |
| Abnormal ECG requiring hospitalizationCardiac disorders | 0/187 | 1/183 |
| Transient phrenic nerve palsyNervous system disorders | 1/187 | 0/183 |
| Event | Tailored | Anatomical |
|---|---|---|
| Covid-19Infections and infestations | 12/187 | 10/183 |
The baseline safety population included all randomized participants who underwent their first ablation procedure.
| Age, Continuous(years) | Tailored | Anatomical | Total |
|---|---|---|---|
| Mean | 66.4 ± 8.5 | 64.9 ± 8.5 | 65.7 ± 8.5 |
| Sex: Female, Male(Participants) | Tailored | Anatomical | Total |
|---|---|---|---|
| Female | 42 | 35 | 77 |
| Male | 145 | 148 | 293 |
| Race and Ethnicity Not Collected(Participants) | Tailored | Anatomical | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Tailored | Anatomical | Total |
|---|---|---|---|
| Netherlands | 3 | 2 | 5 |
| Belgium | 6 | 4 | 10 |
| United States | 29 | 30 | 59 |
| France | 128 | 124 | 252 |
| Germany | 21 | 23 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Dec 2023, 34 months.
Results were first posted in Sep 2025, 1 year 8 months after primary completion.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 34 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Volta Medical